Skip to main content

MADRIGAL PHARMACEUTICALS INC

For the period ended Mar 31, 2024. Filed May 7, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 7, 2024

MDGL$432.79+8.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

ItemDescriptionPage
Part I. Financial Information3
Item 1.Financial Statements (Unaudited):3
Condensed Consolidated Balance Sheets at March 31, 2024 and December 31, 20233
Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2024 and 20234
Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2024 and 20235
Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2024 and 20236
Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2024 and 20237
Notes to Condensed Consolidated Financial Statements8
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations23
Item 3.Quantitative and Qualitative Disclosures About Market Risk30
Item 4.Controls and Procedures30
Part II. Other Information31
Item 1.Legal Proceedings31
Item 1A.Risk Factors31
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds32
Item 3.Defaults Upon Senior Securities32
Item 4.Mine Safety Disclosures32
Item 5.Other Information32
Item 6.Exhibits33
Signatures36
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.